Foltene Pharma

Foltene Pharma, based in Greece, focuses on developing and distributing innovative dermocosmetic products aimed at improving hair, scalp, and nail health through scientifically formulated treatments. Founded in 1944, Foltene Pharma specializes in dermocosmetics, particularly in hair and scalp care. The company has taken part in one funding deal, with its most recent deal occurring on October 21, 2025. Foltene Pharma operates with a global presence, headquartered in Athens, Greece.

Foltène® Pharma specializes in the development and distribution of dermocosmetic products primarily focused on hair, nails, and eyebrows. Their core offerings include targeted treatments for thinning hair, oily hair, and sensitive scalps, utilizing exclusive and patented active ingredients such as Tricosaccaride® and Tricalgoxyl®. The product line aims to enhance hair health and aesthetics, addressing concerns related to hair loss and scalp sensitivity. Foltène® Pharma serves a diverse customer base, including men and women seeking effective hair and scalp care solutions, as well as individuals interested in enhancing their eyelashes and eyebrows.

Their products are marketed internationally, particularly in Europe, North America, and select regions in Asia, thereby expanding their reach in the global dermocosmetics sector. Foltène® Pharma generates revenue through direct sales of its specialized hair and scalp treatments, along with its nail and eyelash enhancement products. The company engages in both B2B and direct-to-consumer transactions, collaborating with retailers and wholesalers. The pricing structure reflects the premium nature of their formulations, with individual products designed for specific hair and scalp needs contributing to their overall revenue stream.

By establishing strong distribution channels and maintaining partnerships in the beauty and wellness sectors, Foltène® Pharma effectively captures market share and meets consumer demands for high-quality hair care solutions. Following its acquisition by Judydoll in October 2025, Foltene Pharma aims to leverage its proprietary technologies and global distribution network to enhance their product offerings and expand into new markets. The acquisition is part of a strategy to penetrate the hair and scalp care segment more effectively. Plans include the introduction of new products that utilize advanced formulations and a focus on expanding the company's presence in Europe and North America by the end of 2026.